 Mereo BioPharma Group plc NASDAQ: MREO, AIM: MPH, Mereo or the Company, today announced that it is distributing approximately 1.2 cents cash per Contingent Value Right CVR, a total of approximately 463,748, related to the 4 million upfront milestone payment from the global license agreement with Oncologie, Inc. after deduction of costs, charges and expenditures for the development and commercialization of navicixizumab the License Agreement, completed on January 13, 2020. The distribution will be made by Computershare Inc. to holders of the CVRs by March 17, 2020 in accordance with the terms and conditions of the Contingent Value Rights Agreement for former stockholders of OncoMed Pharmaceuticals, Inc. OncoMed, dated April 23, 2019, by and among Mereo and Computershare Inc., as rights agent, the Mereo CVR Agreement. 